Should the Arteriovenous Fistula Be Created before Starting Dialysis?: A Decision Analytic Approach

Swapnil Hiremath<sup>1,2,3</sup>, Greg Knoll<sup>1,2</sup>, Milton C. Weinstein<sup>3</sup>

1 Division of Nephrology, Kidney Research Center, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada, 2 Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada, 3 Department of Health Policy and Management, Harvard School of Public Health, Boston, Massachusetts, United States of America

Abstract

**Background:** An arteriovenous fistula (AVF) is considered the vascular access of choice, but uncertainty exists about the optimal time for its creation in pre-dialysis patients. The aim of this study was to determine the optimal vascular access referral strategy for stage 4 (glomerular filtration rate <30 ml/min/1.73 m<sup>2</sup>) chronic kidney disease patients using a decision analytic framework.

**Methods:** A Markov model was created to compare two strategies: refer all stage 4 chronic kidney disease patients for an AVF versus wait until the patient starts dialysis. Data from published observational studies were used to estimate the probabilities used in the model. A Markov cohort analysis was used to determine the optimal strategy with life expectancy and quality adjusted life expectancy as the outcomes. Sensitivity analyses, including a probabilistic sensitivity analysis, were performed using Monte Carlo simulation.

**Results:** The wait strategy results in a higher life expectancy (66.6 versus 65.9 months) and quality adjusted life expectancy (38.9 versus 38.5 quality adjusted life months) than immediate AVF creation. It was robust across all the parameters except at higher rates of progression and lower rates of ischemic steal syndrome.

**Conclusions:** Early creation of an AVF, as recommended by most guidelines, may not be the preferred strategy in all pre-dialysis patients. Further research on cost implications and patient preferences for treatment options needs to be done before recommending early AVF creation.

Introduction

The burden of chronic kidney disease (CKD) continues to increase, with 571,414 patients in the end-stage renal disease (ESRD) program in the United States in 2009 [1]. The majority of these patients, 398,861, are on hemodialysis. An even greater number of patients have advanced kidney failure with a glomerular filtration rate less than 30 ml/min/1.73 m<sup>2</sup> (Stage 4 CKD) [2]. In the United States alone, it is estimated that 0.35% of the adult population has stage 4 CKD, which translates into more than 800,000 people. In 2009, 116,395 CKD patients progressed to ESRD and started hemodialysis in the United States [1].

The arteriovenous fistula (AVF) has been identified as the optimal vascular access for hemodialysis patients based on improved survival and fewer complications as compared to arteriovenous grafts (AVG) and tunneled central venous catheters (CVC) [3]. Despite this, more than 80% of incident hemodialysis patients start with a CVC as their vascular access [1]. Timely creation of an AVF before the need for dialysis therapy may allow adequate time for the fistula to mature as well as provide sufficient time to perform another vascular access procedure if the first attempt fails, thus obviating the need for a CVC, though firm evidence for the same is lacking [4,5]. Hence, most guidelines recommend assessment of patients for access creation at the CKD 4 stage [5–9].

However, early AVF creation is not without problems. A small number of patients may develop ischemic steal syndrome from arterial ischemia in the distal limb or develop high output heart failure. Both of these complications usually require AVF ligation [10,11]. In addition, early AVF creation, prior to dialysis, will likely result in many patients undergoing unnecessary surgery since most stage 4 CKD patients are much more likely to die than to actually develop ESRD and require dialysis [12]. Lastly, greater than 25% of AVF may never mature enough to be used functionally [13].

Thus creation of an AVF when a patient has stage 4 CKD but is not yet on dialysis has both risks and potential benefits. There are no validated prediction models to determine which patients will progress to ESRD and thus should have an AVF created. Therefore, patients in stage 4 CKD have two options; they can either proceed with early AVF creation or start dialysis with a CVC and proceed with AVF later. We used a decision-analytic model to compare these two treatment options faced by patients with stage 4 CKD. The model estimated survival as well as quality-adjusted survival.
Methods

The Decision Model

We used a Markov model to compare two treatment strategies for stage 4 CKD patients: (1) AVF strategy and (2) Wait strategy. In the model, hypothetical cohorts of patients are followed for the remainder of their lifetimes [14]. With each monthly ‘cycle’ of the model, patients may move between several different health states (e.g. CKD stage 4 with no AVF, CKD stage 4 with AVF, Dialysis with CVC, Dialysis with AVF, death) according to the occurrence of clinical events (e.g. progression to dialysis, development of heart failure due to AVF, etc). The probabilities that each of these events occurs was determined using the best available data from the literature. Because some of the transition probabilities depend on the time since entering a state (such as mortality after starting dialysis), we created “tunnel” states which are essentially copies of a state that track the length of time spent in the state [15].

By simulating outcomes in large numbers of identical patients, the average accumulated survival time with the two treatment strategies may be estimated. For our base case analysis, we chose a 70-year-old patient with CKD stage 4, because the 65–74 year age group is the fastest growing segment in the dialysis population [1]. It also represents a cohort where clinical equipoise regarding the optimal strategy is the greatest [16].

Our decision model (Figure 1) evaluated the following two treatment strategies:

1. AVF Strategy: CKD stage 4 patients get referred for an AVF; and
2. Wait Strategy: CKD stage 4 patients are not referred for an AVF. When they reach the point of starting dialysis, they get a CVC as their vascular access and are then referred for AVF surgery.

During each cycle of the model (1 month in this analysis), hypothetical patients in any given health state are at risk of several events, which may result in transitions to other health states. For certain health states, we created “tunnel” states to force patients to remain in that state for a fixed number of cycles (e.g. to account for a three-month maturation period for AVF). Stage 4 CKD patients may progress to dialysis; CKD or dialysis patients with an AVF may develop heart failure or ischemic steal syndrome; patients with a CVC may develop central vein stenosis; death may occur while they are still in CKD stage 4 or while they are on dialysis.

Assumptions

The base case was that of a 70 year old man with CKD stage 4. We assumed that the only choice of renal replacement therapy (RRT) for this patient was hemodialysis; peritoneal dialysis and renal transplantation were not considered in this analysis.

In the AVF strategy:

1. All patients with CKD stage 4 would be referred for an AVF; it would take 2 months to create an AVF and 3 months for it to mature and be functional.
2. If an AVF failed, another attempt to make an AVF would not be made.
3. If a patient with an AVF developed CHF or steal, the AVF would be ligated in the same month. Hence heart failure and steal syndrome were modeled as temporary health states.

In the wait strategy:

1. All CKD 4 patients progressing to need dialysis would start with a CVC.
2. Once on dialysis, they would all be referred to get an AVF, with the same waiting and maturation period as above.
3. During the 2 cycles of waiting to get AVF surgery, a proportion of patients would decide not to have an AVF and remain on dialysis with a CVC.

Probabilities

Estimates and plausible ranges of event probabilities were obtained from published articles and expert opinion (Table 1). Both deterministic threshold analyses and probabilistic sensitivity analyses were performed, as described below.

We identified 8 studies in the literature on mortality and progression to ESRD for stage 4 CKD patients [12,17–23] (Table 2). The rates of progression varied from a low of 4.27 per 100 person-years from a cardiac database [12] that likely had many patients with ischemic nephropathy, to a high of 14.3 per 100 person-years [20] from a nephrology database that had a significant proportion of proteinuric patients at high risk for progression. For our base case we used data from O’Hare et al [21] (mortality rate 11.68 per 100 person-years) with the extreme values used for sensitivity analyses. The mortality rate for stage 4 CKD patients ranged from a low of 4.5 per 100 person-years to a high of 33.45 per 100 person years in the same 2 studies [12,20]. As for progression, we used data from the O’Hare study [21], (mortality rate 11.68 per 100 person-years) with the extreme values used for sensitivity analyses.

Figure 1. Schematic representation of the decision-analysis model.

doi:10.1371/journal.pone.0028453.g001
Six studies were identified which reported on mortality rates for patients starting dialysis with a CVC or fistula [24–29] (Table 3). The two studies in prevalent patients were published in 2001 and 2002, comprised younger patients (mean age <60 yrs), and had mortality rates of 7.29 to 13 per 100 person-years for patients with an AVF and 15.16 to 23 per 100 person-years for patients with CVC [25,27]. In contrast, the more recent studies included older, incident patients with higher mortality rates [24,26,28,29]. The mortality rate in patients with CVC, however, was approximately 1.5 to 2 times that of patients with an AVF in all the studies [24–29]. We used data from Xue et al. for our base case, since that study provided separate mortality rates according to access type for the first 90 days of dialysis and thereafter as well as included elderly patients in the 65–74 age range [29]. A tunnel state was created to account for the fact that the mortality rate is significantly higher in the first three months of dialysis before it levels off.

Rates of fistula failure were obtained from a Dutch prospective study [30]. Fistula failure rates due to the loss of fistula patency before cannulation were used to model failure rates in the CKD stage. Functional failure, which refers to loss of fistula patency after cannulation, was used to model failure rates in the dialysis states. We incorporated secondary fistula failure rates, which include intervening manipulations designed to re-establish or maintain the

### Table 1. Probabilities and Utilities.

| Variables                                      | Best Estimate | Range (for sensitivity analysis) | Distribution | Reference |
|-----------------------------------------------|---------------|----------------------------------|--------------|-----------|
| Rate of progression to ESRD                   | 0.0076        | 0.00356–0.019                    | Lognormal    | 19        |
| CKD stage 4 mortality                         | 0.0097        | 0.00375–0.0279                   | Lognormal    | 19        |
| Mortality on dialysis with CVC in first months | 0.042         | 0.0126–0.0503                    | Lognormal    | 27        |
| Mortality on dialysis with CVC after three months | 0.020       | 0.0126–0.0503                    | Lognormal    | 27        |
| Mortality on dialysis with AVF in first months | 0.018         | 0.0061–0.0232                    | Lognormal    | 27        |
| Mortality on dialysis with AVF after three months | 0.013         | 0.0061–0.0232                    | Lognormal    | 27        |
| Patient refusal for an AVF                    | 0.0467        | 0.01–0.1                         | Beta         | 29        |
| Central vein stenosis                         | 0.017         | 0.001–0.05                       | Beta         | 29        |
| Heart Failure due to AVF                      | 0.0004        | 0.001–0.09                       | Lognormal    | Expert opinion |
| Mortality due to heart failure                | 0.012         | 0.01–0.5                         | Beta         | Expert Opinion |
| Surgical mortality                            | 0.001         | 0.0001–0.005                     | Beta         | Expert opinion |
| Ischemic steal syndrome                       | 0.0504        | 0.001–0.09                       | Lognormal    | 29        |
| AVF Failure: first three months               | 0.025         | 0–0.9                            | Lognormal    | 28        |
| AVF Failure: after three months               | 0.016         | 0–0.9                            | Lognormal    | 28        |
| AVF failure on dialysis                       | 0.010         | 0–0.9                            | Lognormal    | 28        |
| Utility of CKD stage 4 without AVF            | 0.62          | 0.40–0.84                        | Triangular   | 31        |
| Utility of CKD stage 4 with AVF               | 0.62          | 0.40–0.84                        | Triangular   | 31        |
| Utility of dialysis                           | 0.51          | 0.20–0.82                        | Triangular   | 31        |

### Table 2. Summary of literature on mortality and progression to ESRD in CKD stage 4.

| Study              | Mean age (years) | GFR (ml/min) | Progression to ESRD | Mortality | Population                  |
|--------------------|------------------|--------------|---------------------|-----------|-----------------------------|
| Keith (2001)       | 73.6 ± 13.6      | 15–29        | 19.9%*              | 45.7%*    | Large HMO                   |
| Go (2004)          | 70.1 ± 14.5      | 15–29        | 14.2 per 100 PY     | 11.36 per 100 PY | Large HMO                   |
| Patel (2005)       | 70.0 ± 10.0      | 15–29        | 9.31 per 100 PY     | 11.68 per 100 PY | Veterans                   |
| O’Hare (2007)      | 65–74            | 15–29        | 6.31 per 100 PY     | 15.39 per 100 PY | Veterans                   |
| O’Hare (2007)      | 75–84            | 15–29        | 4.27 per 100 PY     | 33.45 per 100 PY | Post acute cardiac event   |
| Rodrick (2009)     | 83.2 ± 7.1       | < 30         | 19–29 per 100 PY    | 19–29 per 100 PY | UK General Practice        |
| Keough-Ryan (2008) | 66.8 ± 14.5      | < 30         | 14.3 per 100 PY     | 4.5 per 100 PY | Referred population         |
| Levin (2008)       | 71.6             | < 30         | 3.8%†               | 10.4%†    | Referred population         |

*crude data in percentages, over 66 months of follow up.
†crude 1 year data in percentages.
‡Age-Standardized Rates.
PY: patient-years.
HMO: Health Maintenance Organization.
doi:10.1371/journal.pone.0028453.t002
functionality. Tunnel states were created to account for the high fistula failure rates in the first 3 months after creation which plateau thereafter. The probabilities of developing steal syndrome and central vein stenosis, and of refusing dialysis, were derived from a cross-sectional study [31]. Since there were only case reports and no summary estimates of the incidence rate of high output heart failure with AVF, it was assumed to be 5 per 1000 patient-months based on expert opinion (SH, GK). Since there were no data on operative mortality rate for an AVF creation or ligation surgery, it was similarly assumed to be 1 in 1000 based on expert opinion (SH, GK). Both of these subjective estimates were subjected to sensitivity analysis.

Outcomes
Life expectancy with each strategy was calculated based on the average accumulated survival time. Quality-adjusted life expectancy was calculated by weighting the time spent in each state with the preference-based utility of that state [32]. The utilities for the health states of CKD stage 4 and dialysis were obtained from a Canadian study that measured the Short Form-6D (SF-6D) and Health Utilities Index Mark 3 (HUI), the latter of which was used [33]. We assumed that an AVF would not result in a significant disutility for CKD stage 4 patients. We also assumed that utilities for dialysis patients with CVC and AVF would be the same; sensitivity analyses were performed to test these assumptions. Utilities assigned to each month were the average of those for the patient’s health state at the beginning and end of the month [34].

Analysis
The analysis was done using a Markov cohort method with 100,000 patients. Model verification (debugging) was done by building up the model from simple to more complex, checking each step visually, examining the state probabilities from the cohort analysis, exploring certain extreme values and doing a sensitivity analysis on all variables. The model was calibrated by comparing simulated events (mortality for dialysis patients in the model) to observed ones (from the USRDS report) [1]. A probabilistic sensitivity analysis was done by assigning probability distributions around model parameters and by using Monte Carlo simulation [35] (table 4). All analysis was done using TreeAge Pro 2008 software (version 1.3.1, Williamstown, MA) and JMP (version 8.0, SAS Inc., Cary, NC).

Table 3. Summary of literature on difference in mortality with CVC and AVF.

| Study               | Mean age | Mortality with AVF (per 100 PY) | Mortality with CVC (per 100 PY) | Population          |
|---------------------|----------|--------------------------------|--------------------------------|---------------------|
| Dhingra (2001)      | 59.2     | 13\(^2\)                       | 22\(^2\)                       | Prevalent, DMMS Wave 1 |
| Dhingra (2001)      | 59.2     | 11\(^2\)                       | 23\(^2\)                       | Prevalent, DMMS Wave 1 |
| Pastan (2002)       | 58.3 ± 0.2 | 7.29                          | 15.16                          | Prevalent ESRD Network 6 |
| Xue (2003) First 90 days | ~75     | 28.8                           | 60.4                           | Incident Medicare   |
| Xue (2003) Next 9 months | ~75     | 21.6                           | 52.8                           | Incident Medicare   |
| Polkinghorne (2004) | 61 (range 48–71) | 8.6                           | 26.1                           | Incident Medicare   |
| Moist (2008)        | 68 (median) | HR 1.6\(^1\)                  |                                | Incident            |
| Bradbury (2009)     | 62.5 ± 15 | 9.96\(^1\)                    | 53.62\(^1\)                    | Incident, DOPPS I & II |

*Adapted from Adjusted patient survival data.
\(^1\)Hazard ratio, compared to mortality with AVF.
\(^2\)Six month follow up data.
PY: patient-years.
doi:10.1371/journal.pone.0028453.t003

Results

Base Case Analysis
The results of the base case analysis showed that the wait strategy resulted in a slightly higher life expectancy (66.55 vs 65.9 months) and quality-adjusted life expectancy (QALE) (38.89 vs. 38.49 quality-adjusted life months) as compared to the AVF strategy (Table 5).

Table 4. Probability Distributions and parameter estimates used in the Probabilistic Sensitivity Analysis.

| Variables                        | Distribution | Parameters |
|----------------------------------|--------------|------------|
| Rate of progression to ESRD      | Lognormal    | μ = -2.333, σ = 0.406 |
| CKD stage 4 mortality            | Lognormal    | μ = -2.577, σ = 0.415 |
| Mortality on dialysis with CVC in first three months | Lognormal | μ = -5.473, σ = 0.604 |
| Mortality on dialysis with CVC after three months | Lognormal | μ = -6.215, σ = 0.759 |
| Mortality on dialysis with AVF in first three months | Lognormal | μ = -6.320, σ = 0.901 |
| Mortality on dialysis with AVF after three months | Lognormal | μ = -6.645, σ = 0.724 |
| Patient refusal for an AVF       | Beta         | r = 28/n = 599 |
| Central vein stenosis            | Beta         | r = 10/n = 599 |
| Heart Failure due to AVF         | Lognormal    | μ = -9.210, σ = 0.601 |
| Mortality due to heart failure    | Beta         | r = 5/n = 404 |
| Surgical mortality               | Beta         | r = 1/n = 1000 |
| Ischemic steal syndrome          | Lognormal    | μ = -2.987, σ = 0.768 |
| AVF Failure: first three months  | Lognormal    | μ = -3.689, σ = 1.010 |
| AVF Failure: after three months  | Lognormal    | μ = -4.135, σ = 0.970 |
| AVF failure on dialysis          | Lognormal    | μ = -4.605, σ = 1.177 |
| Utility of CKD stage 4           | Triangular   | low = 0.40, most likely = 0.62, high = 0.84 |
| Utility of dialysis              | Triangular   | low = 0.20, most likely = 0.51, high = 0.82 |
doi:10.1371/journal.pone.0028453.t004
Sensitivity Analysis

Multiple one-way sensitivity analyses were carried out for all the variables entered in the model. The optimal strategy changed at very high rates of progression of CKD to dialysis as well at lower rates of steal syndrome than used in the base case analysis. When the rate of progression was higher than 0.01126 (corresponding to 14.5 per 100 patient-years), the optimal strategy was to refer patients for AVF creation (Figure 2). The additional LE and QALE obtained at the highest rate of progression used in the sensitivity analysis were 0.05 and 0.03 months respectively. Similarly, the optimal strategy changed to AVF creation when the probability of steal syndrome was lower than 0.023. The additional LE and QALE obtained with the AVF strategy when there was no steal syndrome were 0.5 and 0.3 months respectively. If the utility of CKD stage 4 patients with an AVF was higher than 0.7 whilst maintaining the utility of CKD stage 4 patients without an AVF at 0.62, the optimal strategy reverted to the AVF strategy. When the fistula failure rates were changed to zero, the optimal strategy did not change. The optimal strategy is also otherwise robust across the range of probabilities tested for all other parameters (Table 1).

A two-way sensitivity analysis with respect to the probabilities of progression and steal syndrome is shown in Figure 3. It demonstrates that as the rate of progression to dialysis increases, the AVF strategy becomes optimal despite increasing probability of steal syndrome.

Incremental outcomes from the probabilistic sensitivity analysis, expressed as a difference of quality adjusted life expectancy obtained between the two strategies, were obtained using a Monte Carlo simulation. The probability that the wait strategy is optimal was 91.7% (Figure 4).

Discussion

In this decision analysis, we have shown that the wait strategy is the optimal strategy for our base case of a 70-year old patient with stage 4 CKD. However, the gains in life expectancy and quality-adjusted life expectancy are likely to be less than one month. The analysis was robust across the range of values for most variables in the model, with the possible exception of the rate of progression to ESRD and the rate of steal syndrome.

These results suggest that recommendations of the Fistula First Breakthrough Initiative and the various society guidelines, to

**Table 5. Results of base case analysis.**

| Strategy | Life expectancy (in months) | Gain in life expectancy | Quality adjusted life expectancy (in months) | Gain in quality adjusted life expectancy |
|----------|-----------------------------|-------------------------|---------------------------------------------|------------------------------------------|
| Wait     | 66.55                       | 0.65                    | 38.89                                       | 0.50                                     |
| AVF      | 65.90                       | -                       | 38.49                                       | -                                        |

doi:10.1371/journal.pone.0028453.t005

Figure 2. One way sensitivity analysis based on rate of progression of CKD stage 4 to dialysis: This demonstrates that the wait strategy results in a higher quality-adjusted life expectancy at lower rates of progression and the AVF strategy results in a higher quality adjusted life expectancy at higher rates of progression of CKD to dialysis.

doi:10.1371/journal.pone.0028453.g002
The wait strategy results in a higher quality-adjusted life expectancy at lower rates of progression and lower probability of ischemic steal and the AVF strategy results in a higher quality adjusted life expectancy at higher rates of progression of CKD to dialysis and higher rates of ischemic steal.

do:10.1371/journal.pone.0028453.g003

Figure 3. Two-way sensitivity analysis plotting rate of progression to dialysis and probability of steal: This demonstrates that the wait strategy results in a higher quality-adjusted life expectancy at lower rates of progression and lower probability of ischemic steal and the AVF strategy results in a higher quality adjusted life expectancy at higher rates of progression of CKD to dialysis and higher rates of ischemic steal.

We did not assess the comparative costs of the two strategies, nor did we perform an incremental cost-effectiveness analysis. Because of the higher number of surgeries in the AVF strategy and the fact that the cost of an AVF surgery is higher than that of CVC insertion, it is likely that the cost would be higher in the AVF strategy, thus making the wait strategy dominant (more QALYs at lower cost) over the AVF strategy.

In summary, this analysis suggests that the optimal strategy in a typical elderly stage 4 CKD patients should be to wait and start with a CVC when required followed by AVF creation. This strategy was robust across most sensitivity analysis. However, it might not be optimal for patients with a very high probability of progression to dialysis, such as patients with proteinuric diabetic nephropathy. Further studies should be done to obtain more precise estimates of progression and develop prediction rules for progression of renal failure in CKD stage 4 which take competing events of death into account.
Acknowledgments

This project was developed initially during the course RDS 288 at the Harvard School of Public Health, course instructor Professor Myriam Hunink. It was also the practicum for the Masters of Public Health for one of the authors (SH) and the other 2 authors (GK and MCW) served as supervisors.

Author Contributions

Conceived and designed the experiments: SH GK MCW. Performed the experiments: SH. Analyzed the data: SH MCW GK. Contributed reagents/materials/analysis tools: SH MCW. Wrote the paper: SH MCW GK.

References

1. U.S.Renal Data System (2011) USRDS 2011 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2011. www.usrds.org. Accessed 2011 Oct 4.

2. K/DOQI Workgroup (2002) Part 4. Definition and classification of stages of chronic kidney disease. Am J Kidney Dis 39: S46–S75.

3. Besarab A (2008) Resolved: Fistulas are preferred to grafts as initial vascular access for dialysis. Pro J Am Soc Nephrol 19: 1629–1631.

4. Murad MH, Sidawy AN, Elamin MB, Rizvi AZ, Flynn DN, et al. (2008) Timing of referral for vascular access placement: a systematic review. J Vasc Surg 48: 31S–33S.

5. Luxton G (2010) The CARI guidelines. Timing of referral of chronic kidney disease patients to nephrology services (adult). Nephrology (Carlton ) 15 Suppl 1: S2–11.

6. K/DOQI Workgroup (2006) Clinical practice guidelines for vascular access. Am J Kidney Dis 48 Suppl 1: S176–S237.

7. Besarab A, Brouwer D (2004) Improving arteriovenous fistula construction: Fistula first initiative. Hemodial Int 8: 199–206.

8. Jindal K, Chan CT, Deziel C, Hirsch D, Soroka SD, et al. (2006) Hemodialysis clinical practice guidelines for the Canadian Society of Nephrology. J Am Soc Nephrol 17: S1–47.

9. Tordoir J, Canaud B, Haage P, Konner K, Basci A, et al. (2007) EBPG on Vascular Access. Nephrol Dial Transplant 22 Suppl 2: ii88–117.

10. MacRae JM, Pandeya S, Humen DP, Krivitski N, Lindsay RM (2004) Arteriovenous fistula-associated high-output cardiac failure: a review of mechanisms. Am J Kidney Dis 43: e17–e22.

11. Scheltinga MR, van HF, Bruijinckx CM (2009) Time of onset of haemodialysis access-induced distal ischaemia [HADl] is related to the access type. Nephrol Dial Transplant.

12. Kroushg-Ryan TM, Kibert BA, Cox JL, Thompson KJ, Clase CM (2008) Development of end stage renal disease following an acute cardiac event. Kidney Int 74: 356–363.

13. Patel ST, Hughes J, Mills JL, Sr (2003) Failure of arteriovenous fistula maturation: an unintended consequence of exceeding dialysis outcome quality Initiative guidelines for hemodialysis access. J Vasc Surg 38: 439–445.

14. Beck JR, Pauker SG (1983) The Markov process in medical prognosis. Med Decis Making 3: 419–458.

15. Hawkins N, Sculpher M, Epstein D (2005) Cost-effectiveness analysis of treatments for chronic disease: using R to incorporate time dependency of treatment response. Med Decis Making 25: 511–519.

16. O'Hare AM, Bertienthal D, Walter LC, Garg AX, Covinsky K, et al. (2007) When to refer patients with chronic kidney disease for vascular access surgery: should age be a consideration? Kidney Int 71: 555–561.

17. Conway B, Webster A, Ramay G, Morgan N, Neary J, Whitworth C, Hart, J (2009) Predicting mortality and uptake of renal replacement therapy in patients with stage 4 chronic kidney disease. Nephrol Dial Transplant 24: 1930–1937.

Figure 4. Incremental outcomes and strategy selection frequency with the probabilistic sensitivity analysis using a Monte Carlo simulation.
doi:10.1371/journal.pone.0028453.g004

Author Contributions

Conceived and designed the experiments: SH GK MCW. Performed the experiments: SH. Analyzed the data: SH MCW GK. Contributed reagents/materials/analysis tools: SH MCW. Wrote the paper: SH MCW GK.
18. Go AS, Chertow GM, Fan D, Mc Culloch CE, Hsu CY (2004) Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351: 1296–1305.

19. Keith DS, Nichols GA, Gullion CM, Brown JB, Smith DH (2004) Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med 164: 659–663.

20. Levin A, Djurdjevic O, Beaucheu M, Er L (2008) Variability and risk factors for kidney disease progression and death following attainment of stage 4 CKD in a referred cohort. Am J Kidney Dis 52: 663–671.

21. O'Hare AM, Choi Ai, Bertenhal B, Bacchetti P, Garg AX, et al. (2007) Age affects outcomes in chronic kidney disease. J Am Soc Nephrol 18: 2758–2765.

22. Patel UD, Young EW, Ojo AO, Hayward RA (2005) CKD progression and mortality among older patients with diabetes. Am J Kidney Dis 46: 406–414.

23. Roderick PJ, Atkins RJ, Smeeth L, Mylne A, Nitsch DD, et al. (2009) CKD and mortality risk in older people: a community-based population study in the United Kingdom. Am J Kidney Dis 53: 950–960.

24. Bradbury BD, Chen F, Furniss A, Pisoni RL, Kern M, et al. (2009) Conversion of vascular access type among incident hemodialysis patients: description and association with mortality. Am J Kidney Dis 53: 804–814.

25. Dhingra RK, Young EW, Halbprecht-Shearon TE, Leavey SF, Port FK (2001) Type of vascular access and mortality in U.S. hemodialysis patients. Kidney Int 60: 1443–1451.

26. Moist LM, Trpeski L, Na Y, Lok CE (2008) Increased hemodialysis catheter use in Canada and associated mortality risk data from the Canadian Organ Replacement Registry 2001-2004. Clin J Am Soc Nephrol 3: 1726–1732.

27. Pastan S, Soucie JM, McClellan WJ (2002) Vascular access and increased risk of death among hemodialysis patients. Kidney Int 62: 620–626.

28. Pollinghoarse KR, McDonald SP, Atkins RC, Kerr PG (2004) Vascular access and all-cause mortality: a propensity score analysis. J Am Soc Nephrol 15: 477–486.

29. Xue JL, Dahl D, Ebben JP, Collins AJ (2003) The association of initial hemodialysis access type with mortality outcomes in elderly Medicare ESRD patients. Am J Kidney Dis 42: 1013–1019.

30. Huijbrigs HJ, Bots ML, Wittens CH, Schramma YC, Moll FL, et al. (2008) Hemodialysis arteriovenous fistula patency revisited: results of a prospective, multicenter initiative. Clin J Am Soc Nephrol 3: 714–719.

31. Graham J, Hiremath S, Magner PO, Knoll GA, Burms KD (2008) Factors influencing the prevalence of central venous catheter use in Canadian haemodialysis centre. Nephrol Dial Transplant 23: 3585–3591.

32. Johansson M, Pinakin J, Weinstein MC (1994) A note on QALYs, time tradeoff, and discounting. Med Decis Making 14: 188–193.

33. Davison SN, Jianggi GS, Freey DH (2008) Comparing the Health Utilities Index Mark 3 (HUI3) with the Short Form-36 Preference-Based SF-6D in Chronic Kidney Disease. Value Health.

34. Naimark DM, Bonn M, Krahn M (2008) The half-cycle correction explained: two alternative pedagogical approaches. Med Decis Making 28: 706–712.

35. Briggs AH (2004) Statistical approaches to handling uncertainty in health economic evaluation. Eur J Gastroenterol Hepatol 16: 551–561.

36. O’Hare AM, Allon M, Kaufman JS (2010) Whether and when to refer patients for predialysis AV fistula creation: complex decision making in the face of uncertainty. Semin Dial 23: 452–455.

37. Ng LJ, Chen F, Pisoni RL, Krishnan M, Mapes D, et al. (2011) Hospitalization risks related to vascular access type among incident US hemodialysis patients. Nephrol Dial Transplant 26: 3658–3666.

38. Vachharajani TJ, Moossavi S, Jordan JR, Vachharajani V, Freedman BI, et al. (2011) Re-evaluating the Fistula First Initiative in Octogenarians on Hemodialysis. Clin J Am Soc Nephrol 6: 1663–1667.

39. Canadian Institute for Health Information (2008) 2007 Annual Report—Treatment of End-Stage Organ Failure in Canada, 1996 to 2005 (Ottawa: CIHI, 2008).

40. Xue H, Lacson E, Jr., Wang W, Curhan GC, Brunelli SM (2010) Choice of vascular access among incident hemodialysis patients: a decision and cost-utility analysis. Clin J Am Soc Nephrol 5: 2209–2216.

41. Pisoni RL, Young EW, Dykstra DM, Greenwood RN, Hecking E, et al. (2002) Vascular access use in Europe and the United States: results from the DOPPS. Kidney Int 61: 303–316.

42. Barlow AD, Doughman TM, Warwick GL, Nicholson ML (2008) A successful scheme for reducing waiting times for arteriovenous fistula formation. J Vasc Access 9: 129–132.

43. Xi W, Harwood L, Diamant MJ, Brown JB, Gallo K, et al. (2011) Patient attitudes towards the arteriovenous fistula: a qualitative study on vascular access decision making. Nephrol Dial Transplant 26: 3302–3309.